A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL- 12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

Brain Cancer
James Markert, MD, MPH
University of Alabama at Birmingham


Gliomas are the most common brain tumor, with glioblastoma multiforme (GBM) being one of the most fatal and treatment-resistant cancers. Survival and time to progression have changed minimally in the past 50 years; thus, new treatments are needed. Direct delivery of tumor-killing viruses is one method that has been researched with promising results. This study aims to use a new therapy called C134. C134 is an oncolytic virus, meaning it is a virus that infects and kills tumors cells but not normal cells. Furthermore, the virus was engineered to have specific proteins that elicit an immune response against surviving tumor cells, which increases the antitumor effect of the therapy.

Trial Registration: ClinicalTrials.gov Identifier: NCT03657576